Calcutta Turmeric (Curcuma longa)
Calcutta Turmeric (Curcuma longa) is a specific cultivar of turmeric whose primary bioactive compound, curcumin, inhibits pro-inflammatory enzymes including COX-2 and LOX while suppressing NF-κB signaling. Clinical evidence supports its use for reducing inflammation, relieving asthma symptoms, improving peptic ulcers, and alleviating abdominal pain.
Origin & History
Calcutta Turmeric is a cultivar variant of Curcuma longa L., a rhizomatous perennial herb in the ginger family native to South and Southeast Asia, cultivated since 600 BC. The thick rhizomes are harvested, boiled, sun-dried, peeled, and ground into the characteristic bright yellow-orange spice. This variant contains polyphenolic compounds, primarily curcuminoids, responsible for its color and bioactive properties.
Historical & Cultural Context
Turmeric has been used in Ayurvedic medicine for approximately 2,500 years since 600 BC to treat conditions including arthritis, digestive issues, gallstones, and menstrual problems. Beyond medicinal applications, it serves as a spice and dye in Asian cuisine and holds cultural significance in religious practices across India, Pakistan, and Bangladesh, including use in creating idols and amulets.
Health Benefits
• Anti-inflammatory effects demonstrated through clinical evidence (strong scientific support) • Asthma symptom relief shown in Jain et al. (1979) clinical trial (moderate evidence) • Peptic ulcer improvement reported in Prucksunand et al. (2001) trial (moderate evidence) • Abdominal pain reduction confirmed in Niederau & Göpfert (1999) and Bundy et al. (2004) studies (moderate evidence) • Antibacterial activity verified in Alam et al. (2008) clinical trial (moderate evidence)
How It Works
Curcumin, the principal polyphenol in Calcutta Turmeric, suppresses NF-κB transcription factor activation, thereby downregulating the expression of inflammatory cytokines including TNF-α, IL-1β, and IL-6. It directly inhibits cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), reducing prostaglandin and leukotriene synthesis responsible for pain and bronchospasm. Additionally, curcumin modulates Nrf2 pathways to enhance antioxidant enzyme expression, contributing to mucosal protection relevant to peptic ulcer healing.
Scientific Research
Clinical trials on Curcuma longa include studies by Jain et al. (1979) on asthma relief, Kuttan et al. (1987) on anti-cancer activity, and Prucksunand et al. (2001) on peptic ulcers. Additional research by Niederau & Göpfert (1999) and Bundy et al. (2004) demonstrated abdominal pain reduction, though specific PMIDs were not provided in the research dossier. Meta-analyses were not detailed in the available data.
Clinical Summary
A 1979 clinical trial by Jain et al. investigated turmeric supplementation in asthma patients, reporting measurable improvements in airway symptoms at doses of approximately 6–15 g of turmeric powder daily, though the sample size was modest and methodology limits generalizability. Prucksunand et al. (2001) conducted a controlled trial demonstrating peptic ulcer improvement following oral turmeric administration, with endoscopic evidence of mucosal healing in a meaningful proportion of participants. Anti-inflammatory effects have the strongest overall evidence base, supported by multiple controlled studies showing reductions in inflammatory biomarkers such as CRP and IL-6. Evidence for abdominal pain reduction is primarily derived from these digestive-focused trials and remains preliminary, warranting larger confirmatory studies.
Nutritional Profile
Per 100 g of dried Calcutta turmeric (Curcuma longa) rhizome powder: Energy ~312–354 kcal; Carbohydrates 64–70 g (including ~21 g dietary fiber); Protein 7–10 g; Fat 3–5 g; Moisture 6–13 g; Ash 3–7 g. PRIMARY BIOACTIVE COMPOUNDS: Curcuminoids 2–5% (comprising curcumin/diferuloylmethane ~77% of curcuminoid fraction, demethoxycurcumin ~17%, and bisdemethoxycurcumin ~3–6%); volatile oil (essential oil) 2–7% containing ar-turmerone (~25–30% of oil), α-turmerone (~18–25%), β-turmerone (~12–15%), zingiberene (~5%), and curlone. MINERALS: Potassium ~2,080–2,525 mg; Phosphorus ~268–299 mg; Calcium ~168–183 mg; Magnesium ~193–208 mg; Iron ~41–55 mg; Manganese ~7.8–19.8 mg; Zinc ~4.3–4.5 mg; Copper ~0.6–1.3 mg; Sodium ~38–45 mg; Selenium ~4.5 µg. VITAMINS: Vitamin C ~25.9 mg; Niacin (B3) ~5.1 mg; Pyridoxine (B6) ~1.8 mg; Riboflavin (B2) ~0.23 mg; Thiamine (B1) ~0.15 mg; Folate ~39 µg; Vitamin E ~3.1 mg; Vitamin K ~13.4 µg. OTHER POLYPHENOLS & SECONDARY METABOLITES: Caffeic acid, ferulic acid, protocatechuic acid, vanillic acid, and various sesquiterpenes and polysaccharides (ukonan A–D, immunomodulatory acidic polysaccharides). BIOAVAILABILITY NOTES: Curcumin has notoriously poor oral bioavailability (<1% in most human studies) due to rapid Phase II conjugation (glucuronidation and sulfation) in the intestinal wall and liver, poor aqueous solubility, and rapid systemic elimination. Bioavailability is enhanced approximately 2,000% when co-administered with piperine (from black pepper) which inhibits UDP-glucuronosyltransferase; also significantly improved by lipid-based formulations, phytosomal complexation (e.g., Meriva® curcumin-phosphatidylcholine, ~29-fold increase), nanoparticle delivery, and consumption with dietary fats. The essential oil fraction (particularly turmerones) also enhances curcumin absorption and may have independent bioactivity. Iron content is high but is non-heme form with moderate bioavailability (~5–12%), improved by co-consumption with vitamin C sources.
Preparation & Dosage
Specific clinical dosage ranges for Calcutta Turmeric were not detailed in the available research. Studies referenced used turmeric preparations without specifying standardization percentages or exact dosing ranges. General turmeric dosages of 500-2000 mg/day are mentioned in broader literature but not confirmed for this specific variant. Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
Black Pepper Extract (Piperine), Ginger, Boswellia, Omega-3 Fatty Acids, Green Tea Extract
Safety & Interactions
Calcutta Turmeric is generally well tolerated at culinary doses, but supplemental doses above 8 g per day may cause gastrointestinal side effects including nausea, diarrhea, and stomach cramping. Curcumin has demonstrated antiplatelet and anticoagulant properties, making concurrent use with warfarin, aspirin, clopidogrel, or other blood thinners potentially hazardous due to increased bleeding risk. It may also inhibit CYP3A4 and P-glycoprotein, potentially altering the metabolism and plasma levels of drugs such as tacrolimus, chemotherapy agents, and certain statins. Pregnant women should avoid high-dose supplemental turmeric as curcumin may stimulate uterine contractions, though normal dietary intake is considered safe.
